Niagen Bioscience, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
NAGE$2.15-5.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets as of and
Unaudited Condensed Consolidated Balance Sheets
(In thousands, except par values)
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents, including restricted cash of $152 for both periods presented | $69,509 | $64,788 |
| Trade receivables, net of allowances of $103 and $147, respectively | 6,840 | 9,741 |
| Inventories | 20,524 | 20,424 |
| Assets held for sale | — | 541 |
| Prepaid expenses and other assets | 3,342 | 1,312 |
| Total current assets | 100,215 | 96,806 |
| Leasehold improvements and equipment, net | 1,216 | 1,323 |
| Intangible assets, net | 5,136 | 5,660 |
| Right-of-use assets, net | 1,657 | 2,192 |
| Other long-term assets | 470 | 425 |
| Total assets | $108,694 | $106,406 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $11,503 | $10,796 |
| Accrued expenses | 3,933 | 7,722 |
| Current maturities of operating lease obligations | 799 | 1,002 |
| Current deferred consideration liability | 535 | — |
| Customer deposits | 137 | 399 |
| Total current liabilities | 16,907 | 19,919 |
| Deferred revenue | 2,162 | 2,674 |
| Operating lease obligations, less current maturities | 1,278 | 1,815 |
| Deferred consideration liability, less current portion | 5,273 | 5,465 |
| Total liabilities | 25,620 | 29,873 |
| Commitments and Contingencies (Note 8) | ||
| Stockholders’ Equity | ||
| Common stock, $0.001 par value; authorized 150,000 shares; 79,030 shares and 79,714 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 79 | 79 |
| Additional paid-in capital | 241,416 | 240,991 |
| Accumulated deficit | (158,420) | (164,528) |
| Cumulative translation adjustments | (1) | (9) |
| Total stockholders’ equity | 83,074 | 76,533 |
| Total liabilities and stockholders’ equity | $108,694 | $106,406 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.